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used the unique model of the SDR for our study of pituitary regulation of fetal growth. The dwarfism results from an autosomal recessive mutation (gene symbol dr) in the GH gene (1 1). The point mutation causes abnormal splicing and a one-base deletion in the GH mRNA. Consequently, the G H mRNA is present in reduced amounts in the SDR, at 2.6 to 6% of that in the normal rat (12, 13) , and the small amounts of G H mRNA produced are nontranslatable, resulting in complete absence of G H protein.
No GH was detected in the SDR pituitary by PAGE, immunoblot analysis, or RIA (1 2, 14-1 6). GH-containing cells are also absent in the SDR pituitary, as determined by immunocytochemistry. However, it appears to be an isolated deficiency, inasmuch as the presence of prolactin-, ACTH-, TSH-, and LH-producing cells remained unaffected (1 2). Although the G H deficiency of the SDR results in body weights than are 30 to 40% of normal Sprague-Dawley rats at 10 wk of age, SDR males and females are reproductively competent and otherwise healthy ( 1 1). We used the unique characteristics of the SDR model to answer the question: Does Pituitary GH in the late gestation fetal rat contribute to the regulation of fetal growth and the IGF-IGFBP axis? By capitalizing on the genetic transmission of the G H deficiency, we initiated the appropriate crosses and were able to analyze the growth of a combination of affected GH-deficient and GH-normal fetuses that had developed within the same litter. The advantages of our system include: 1) an isolated G H mutation that maintains normal levels of other pituitary hormones and allows a specific investigation of the role of GH in fetal growth; 2) complete GH deficiency; 3 ) reliable categorization of animals based solely on pituitary GH content; 4) a noninvasive method of observing late gestation fetal growth; and 5) a uniform, controlled maternal environment for both dwarf and normal pups. Through this model, we have further examined the nature of fetal growth by illustrating the role of pituitary GH in the regulation of somatic and organ growth, IGF, and IGFBP.
MATERIALS AND METHODS
Animals. The strain of SDR was generously provided by Dr. S. Okuma (Morishita Pharmaceutical Co., Ltd., Shiga, Japan). The original dr/dr females were crossed with dr/dr and Dr/dr males to increase our breeding stock for fetal studies. The resulting animals were classified as dr/dr GH-deficient or Dr/dr GHnormal according to their postnatal growth curves. As demonstrated in previous studies, the dr/dr dwarf rats showed significant inhibition of growth, to less than half the weights of SpragueDawley control rats by postnatal d 30. However, the somatic growth of Dr/dr animals were not different from those of normal Dr/Dr Sprague-Dawley rats of the same postnatal age (Glasscock GF, unpublished data) . For the purpose of categorizing the fetal pups, we formed two phenotypic groups based on GH expression: complete GH-deficient and GH-normal. Because their expression of pituitary GH and their postnatal growth curves were comparable (see below), making Dr/dr and Dr/Dr pups indistinguishable without genetic investigation, both were used in the GH-normal (Dr) group for comparison to the GH-deficient (dr) dwarfs.
To control the maternal size, nutrition, and hormonal environment, only Dr/dr GH-normal females from this stock were used. They were crossed predominantly with Dr/dr males, to achieve a combination of GH-deficient and GH-normal pups within the same litter. However, pups from a cross between a Dr/dr female and dr/dr male were also included in our results because the mean pituitary GH levels, somatic growth, organ weights, and IGF levels of each of the two populations in the litter were not significantly different from those of the same phenotype group from Dr/dr x Dr/dr crosses. Thus, paternal factors appeared to have no additional influences other than their direct genetic contribution to GH gene expression. Six litters, each including 10 to 12 pups/litter, were considered in the study for a total of 64 pups.
All rats were housed in 12-h light, 12-h dark animal facilities, with ambient temperature adjusted to 25°C. Wayne rodent blok (Premier Lab Diets, Bartonville, IL) and tap water were provided ad libitum. These protocols for animal use were approved by the Department of Laboratory and Animal Medicine, Stanford University.
Growth parameters. Body weight, measured on a digital scale (model S300D, Fisher Scientific, Pittsburgh, PA) to 0.01 g, and tail length, measured from the anus to the tip of the tail, were obtained at the time of birth. Because the tail is composed of vertebral bodies, rat tail length provides an easily measurable index of skeletal growth.
Serum collection and organ weights. Pups were killed by decapitation within 3 h of delivery. Because the pups were removed immediately after birth, their state primarily represented the condition of a late-gestation fetus. Although there are many changes in hormonal status and a certain amount of extracellular free water loss during the perinatal period (17, 18) , any such effect was minimized by the promptness of death and is not likely to have greatly altered the birth weights or the other parameters measured. Any perinatal changes would also, presumably, affect both GH-deficient and GH-normal pups to an equal degree. Thus, any data taken immediately after birth are likely to be representative of intrauterine development.
Blood was collected from the cervical stumps, placed on ice, and centrifuged at 12 000 rpm for 15 min. Serum was withdrawn and frozen at -20°C for later assay of IGF and IGFBP. Pituitaries were removed and frozen at -20°C for GH assay. Individual serum samples obtained from GH-deficient and GH-normal pups were pooled after determination of pituitary hormone levels by GH RIA. In each group, two to three individual samples were randomly pooled together to form a volume sufficient for assay.
Individual organs were quickly removed, blotted free of blood, and weighed on a digital scale (model S300D, Fisher Scientific). Livers were frozen in liquid nitrogen at -70°C within 15 min of decapitation. Due to the difficulty of obtaining accurate (fat-free) weights for ovaries, testes, and adrenals in the newborn pups, these organs were not examined.
Distinguishing genotype. Individual pituitary samples were separately homogenized in 300 pL of PBS and 1 % Triton X. Pituitary GH was measured by RIA using lZSI-rGH as the radioligand, a monkey anti-rGH primary antibody, and goat antimonkey secondary antibody. The antiserum (NIDDK-anti-rGH-S-5) was obtained from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Iodination was performed according to the iodogen method. Five pg of ffiH in PBS were reacted with 0.3 mCi IZSI. Reaction was stopped after 5 to 8 min by the addition of 100 pL of phosphate buffer G H and free IZSI were fractionated on a 45 x 0.5 cm column containing Sephadex G-50 in PBS with 0.5% BSA.
The purpose of the RIA was to categorize the individual newborns as either GH-producing or GH-deficient. The crossreactivity of the antiserum with prolactin was less than 0.16%. The lower limit of sensitivity for GH by RIA was 0.4 pg/L (ng/ mL). Pituitary GH levels below this limit were categorized as undetectable and considered indicators of GH-deficient animals. Eighteen of the 64 newborns were included in this category. Other animals with detectable pituitary GH levels were considered GH-normal. There appeared to be a broad range of pituitary GH levels represented in the GH-normal group; Dr/Dr and Dr/ dr animals did not separate into two distinct subpopulations. according to different levels of pituitary GH expression. To avoid any possibilities of errors in grouping resulting from contamination during homogenization or assay or due to RIA sensitivity. we excluded from consideration 13 animals with less than 1 pg of pituitary GH in the sample volume. The remaining 33 animals, all with pituitary GH greater than this level, were grouped as GH-normal. Because significant sexual dimorphic differences in somatic growth were not shown to be present in the SDR until 146 KIM !:' postnatal d 20 (Glasscock GF. unpublished data) . both male and female pups were included in both groups.
RIA 01' IGF-1 and IGF-II. Serum samples were chromatographed in 0.25 M formic acid on a 0.9 x 100 cm column containing Sephadex G-50 (Pharmacia Fine Chemicals, Piscataway. NJ). The fractions eluting between 50 and 67 mL, which contained 90% of the IGF activity and no demonstrable IGFBP, werc collected in siliconized glass tubes containing 1.0 mL of 1 % BSA, frozen, and lyophilized. Serum IGF-I was measured by RIA using 1'51-IGF-I as radioligand and a polyclonal anti-somatomedin-C antibody. This antiserum (UBK487) was a generous gift from the hormone distribution program of the NIDDK and was originally provided by Drs. J. J. Van Wyk and L. E. Underwood (University of North Carolina). Serum IGF-I1 was measured by RIA using '251-IGF-II as radioligand and a monoclonal anti-rat-IGF-I1 antibody (Amano Enzyme Co., Inc., Troy, VA). Lower limits of sensitivity for IGF-I and IGF-I1 by RIA were 0.013 nmol/L (0.1 ng/mL) and 0.067 nmol/L (0.5 ng/mL), respectively.
Pure biosynthetic 59Thr-IGF-I was purchased from Amgen Biologicals (Thousand Oaks, CA). Recombinant IGF-I1 was kindly provided by Michele Smith of Eli Lilly Company (Indianapolis, IN). Iodination was performed by a modification of the chloramine-T technique to sp act of 150-250 pCi/pg for each peptide.
IGFBP untihodies. A polyclonal antibody to partially purified human IGFBP-2 and IGFBP-3 secreted by the human endometrial adenocarcinoma cell line HEC 1A (a-Hec 1) was generated as previously described (19) . This polyclonal antibody has been shown to be specific for rat IGFBP-2 in rat serum (20).
Immlmopr~~cipitation. Stuphylococcus allreas protein A (Pansorbin, Calbiochem, La Jolla, CA) was washed in 50 mmol/L Tris HCI. pH 7.4, and resuspended in Tris buffer at the original volume. Fifty pL of the washed protein A were incubated with 5 ~L L tu-Hec or 5 FL nonimmune rabbit serum on a rotating shelf at 4°C overnight. Samples (20 pL of 1: 10 diluted pooled sera) were then added to the antibody-Staph-A complex and incubated at 4°C on a rotating shelf for 3 h. The samples were then microcentrifuged at 15 000 rpm for 5 min, and the pellet was washed three times with Tris buffer to remove BP nonspecifically immunoprecipitated by the antibody. Samples were prepared for electrophoresis by the addition of sample buffer (Tris-SDS, glycerol), vortexed, boiled for 5 min, revortexed vigorously, and centrifuged at 15 000 rpm for 10 min. The resulting supernatants were electrophoresed, electrotransferred, and ligand blotted with IZ5I-IGF as described below.
Mcwsurc~rnent of IGFBP: SDS-PAGE. SDS-PAGE was performed according to the method of Laemmli (2 1). Twenty pL of 1 : 10 diluted serum were applied per lane to a 4% stacking gel and electrophoresed through a 10% polyacrylamide gel. Prestained molecular weight standards (Bethesda Research Laboratories, Gaithersburg, MD) were run in parallel lanes. Some binding protein samples were enzymatically deglycosylated using Endo F (Calbiochem) as previously described (19) . Gels were run overnight at 50 V.
Elc~ctrotransfir and Western ligand blotting. After electrophoresis, polyacrylamide gels were washed in Towbin buffer (0.025 M Tris-base, 0.192 M glycine, 20% methanol) for 15 min to remove SDS before electrotransfer. Proteins were electroblotted onto nitrocellulose (0.45 mM, Schleigher and Schuell, Inc., Keene, NH) with a Gelman Biotrans semidry electrophoresis transfer unit (Gelman Sciences, Ann Arbor, MI) using Towbin buffer (TBS) (22). Western ligand blotting was carried out by the method of Hossenlopp et al. (23) . Nitrocellulose membranes were washed with TBS (0.15 M sodium chloride, 0.0 1 M Tris HCL) containing 3% Nonidet P-40 (Sigma Chemical Co., St. Louis, MO). Membranes were blocked with TBS containing I % BSA (Sigma) for 2 h, followed by TBS containing 0.1 % Tween for 10 min. The membranes were then incubated overnight at 4°C with approximately 1.5 x lo6 cpm of an equal amount of 1251-IGF-I and -1GF-I1 in 20 mL TBS containing 1% BSA and 0. I % Tween. Membranes were washed with TBS and air-dried, and binding proteins were visualized by exposure on Kodak XOmar AR film (Rochester, NY) for 3-7 d at -70°C. Autoradiograms were scanned using a laser densitometer (Ultrascan XL: LKB, Bromma, Sweden). The absorbance units x mm were measured for each of the major binding proteins.
RNA analy.sis. Total cellular RNA was isolated from liver tissue from GH-deficient and GH-normal newborn pups. Isolation was performed by a modification of the guanidinium isothiocyanate-LiC1 precipitation method (24). Briefly, approximately 1 g tissue was dissolved in I mL GTE buffer [4.5 mol/L guanidinium isothiocyanate, 50 mmol/L N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (pH 7.0), 10 mmol/L EDTA. and 5% 2-mercaptoethanol]. The solution was made 2 mM for LiCI, and RNA was allowed to precipitate for 48 h at 4°C. The precipitated RNA was pelleted by centrifugation for 10 min at 10 000 x g a t 4"C, washed twice with cold 3 M LiCI, and finally dissolved in 1 mL 10 mM Tris-HCI (pH 7.4), 0.05% SDS (TS). RNA was deproteinized by two phenol-chloroform extractions and a single chloroform extraction. After ethanol precipitation, RNA was dissolved in TS, quantified spectrophotometrically, and stored at -70°C. RNA samples were size-fractionated in a 1.2% agarose-formaldehyde gel. transferred onto nitrocellulose, and hybridized with rat cDNA for IGFBP-2, IGFBP-1. and IGFBP-4 according to the method of Wahl et al. (25) . The blot was washed twice for 10 min at 55°C in 0.2 x SSC (sodium chloride, sodium citrate) -0.5% SDS, air dried, and exposed to XAR film (Eastman Kodak. Rochester, NY) at -70°C with an intensifying screen (Dupont, Wilmington, DE) for 1-4 d. The cDNA probe for rat IGFBP-2 was a 1295-bp EcoRI restriction fragment of the 1500-bp cDNA isolated from a rat liver cDNA library and contained the whole coding region. The probe for human IGFBP-I, cross-reacting with rat IGFBP-1, was a 367-bp PstI-BamHI coding region fragment of the HepG2 IGFBP cDNA (26). The probe for human IGFBP-4 was a 440-bp SmaI-restriction fragment of the 1.2-kb cDNA isolated from a hunian osteosarcoma cell gene library (27). The probes were generously provided by Drs. J. Schwander (Basel, Switzerland), D. Powell (Houston, TX), and M. Mohan (Loma Linda, CA), respectively, and were labeled with 32P-dCTP (Amersham Co., Arlington Heights, IL) by random priming using a commercial kit (Pharmacia, Uppsala, Sweden).
Statistical anul.vsis. Student's t test was used for determination of statistically significant differences between the two groups for body weight, tail length, organ weights and organ weight ratios, serum IGF levels, and absorbance units for IGFBP. Figure IA , body weight was modestly but significantly decreased in GH-deficient pups at birth (d 0). The mean birth weight of GH-deficient fetuses, 5.0 k 0.1 g (mean + SEM), was 14% less than the GH-normal pups at 5.8 + 0.1 g ( p < 0.0001). However, tail length showed no pituitary dependency (Fig. IB) . Mean tail length of GHdeficient pups was 16.8 f 0.3 mm as compared with 16.9 f 0.2 mm in GH-normal pups. At birth, the tail length of GH-deficient pups was not different from that of GH-normal pups, thereby demonstrating the significant effect of GH on fetal body weight. but not skeletal growth.
RESULTS

Fetal somatic growth. As illustrated in
Fetal organ weights. Table I compares organ weight data between GH-normal and GH-deficient fetuses at birth. Among the organs listed, there appear to be three patterns of growth evident from organ weights at birth. The growth of the brain was preserved, regardless of its hormonal environment; brain weight in GH-deficient pups was 97% of the GH-normal group. The weight of the lungs was also comparable in both groups. increasing (but not significantly) in GH-deficient fetuses to 114% of control values. To further demonstrate the selective effects of fetal pituitary GH on organ growth, the absolute weights were corrected for their corresponding body weights and presented as an organ weight ratio. This showed the brain and lungs of GHdeficient pups to grow in excess of body weight, at 1 15 and 129% of GH-normal control values, but only the brain weight ratios were significantly increased ( p < 0.0001). The brain, therefore, remains pituitary-independent during the fetal period. and its growth persists despite the inhibition of body weight growth shown in the GH-deficient animals. This pattern of growth observed in the brain and, to a lesser extent, in the lung is continued in the neonatal period (4) . In contrast, growth of the heart. liver, and kidneys was clearly inhibited. Their weights in GH-deficient fetuses were 8 1-88% of GH-normal controls and were significantly different ( p < 0.01 for kidneys, p < 0.00 1 for heart, and p < 0.000 1 for liver). Based on organ weight ratios, these organs were also shown to grow in proportion to body weight (Table 1) . Liver growth was only slightly decreased in comparison to body weight in GH-deficient fetuses, at 95% of the GH-normal ratio. Thus, it appears that the growth of the heart, kidneys, and liver in the late gestation fetus is pituitary-dependent and proportional to overall somatic growth. The moderate pituitary dependence of the heart, liver, and kidney also continues and is amplified during the neonatal stage (4) .
Finally, the inhibition of splenic weight was greatest, but the 43% decrease in absolute weight and 32% decrease in splenic weight ratio in the GH-deficient pups did not reach statistical significance because of relatively large individual organ weight variability. The inhibitory effect shown here in the spleen has been shown to be more dramatic in the neonatal period (4) .
Fetal serzrm IGF levels. In Figure 2A and B, serum IGF levels are plotted for GH-normal and GH-deficient fetuses. Serum IGF-I levels in GH-deficient pups of 2.5 f 0.1 nmol/L (19 + 1 ng/ mL) (mean f SEM) were dramatically lower in comparison to those of GH-normal pups, measuring only 27% of the GHnormal group ( p < 0.0001). Fetal IGF-I1 levels were also greatly affected by the absence of pituitary GH. Figure 2B displays a drop of 52% in the GH-deficient group to 12.5 f 0.8 nmol/L (93 + 6 ng/mL). The attenuated expression of IGF-I and -11 in the GH-deficient pups demonstrates the partial GH-dependent nature of IGF in the fetus.
Western ligand blots of serum IGFBP. Figure 3A shows the results of a Western ligand blot performed on pooled GHdeficient (dr) and GH-normal (Dr) sera. In addition. pooled sera from newborn controls (nb) are shown (lane 13). Only one major BP band, at approximately 26-30 kD, was visualized on the blot. Previous work in neonatal rats (28, 29) has shown the band to be composed of IGFBP-1, nonglycosylated or proteolyzed IGFBP-3, and, as a major contributor, IGFBP-2. The level of IGFBP expression in the newborn control appears comparable to those of the GH-normal (Dr) pools (lanes 7-12). Densitometry was performed to determine relative amounts of the BP in GHdeficient and GH-normal groups, and results are shown in Figure  3 C.
When compared with the GH-normal sera, the absorbancy of the 26-to 30-kD BP complex in GH-deficient sera showed a dramatic increase to 250% of GH-normal values ( p < 0.005).
To more closely examine the nature of the increase in the 26-to 30-kD BP band, a comparison of the BP in both groups after immunoprecipitation with a-Hec-l antibody was conducted (Fig. 3B ). This antibody specifically immunoprecipitates rat IGFBP-2, normally the major neonatal rat serum IGFBP (19, 29) . The first two lanes are Western ligand blots of GH-deficient and GH-normal sera, respectively. Note that the 26-to 30-kD band in GH-deficient serum is more intense than in GH-normal serum, as previously described. The immunoprecipitation of GH-deficient sera (lane 3) resulted in a minor 26-to 30-kD band, compared with its relative abundance in the ligand blot (lane I). Furthermore, the 26-to 30-kD band from the immunoprecipitated GH-deficient sera was considerably less prominent than the same band in the immunoprecipitated GH-normal sera (lane 4). This indicates a decreased relative expression of immunoreactive IGFBP-2 in the 26-to 30-kD region in the sera of GH-deficient pups.
Deglycosylation with Endo F of IGFBP in GH-deficient and GH-normal sera was also performed. The results showed no visible differences between the 26-to 30-kD bands in the lanes treated with Endo F and the untreated lanes, indicating the absence of N-linked glucosamine groups associated with the IGFBP in that complex (data not shown). These findings imply that the 26-to 30-kD band does not contain significant amounts of glycosylated IGFBP-4 or IGFBP-3 fragments (28).
Therefore, the absence of GH in the SDR fetuses was associated with an increased quantity of binding proteins in the 26-to 30-kD band, the same region as IGFBP-2. However, based on immunoprecipitation with a-Hec 1 and studies with Endo F digestion, we conclude that the increased binding protein is not IGFBP-2, glycosylated IGFBP-4, or IGFBP-3 fragments.
Norfhern analysis of IGFBP-I, IGFBP-2, and IGFBP-4 mRNA. Figure 4 shows the results of Northern analysis on liver * Summary of organ wt and organ wt ratios for SDR at birth. Phenotype is indicated above each column and values represent mean f SD. The balues in parentheses represent the GH-deficient organ wt or ratios as a percentage of GH-normal values. The number of organs measured (both lobes of lungs and both kidneys were considered together as one organ) were n = 33 for GH-normal and n = 18 for GH-deficient rats. t Organ wt ratio = organ wt/body wt. $ p < 0.000 1.
$p<O.OOI.
11 11 < 0.0 1.
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tissue taken from GH-normal and GH-deficient pups at birth, ',','. ,,,,,,,,,,,,,, ,,,,,,,,, ,.\\. 
DISCUSSION
Our results demonstrate the incipient pituitary regulation of somatic growth during the late gestation fetal stage of mammalian development in the rat. Previous studies have supported the pituitary-independent nature of fetal growth. Human anencephalic~ have been reported to have normal birth weights. Fetal decapitation in several species, including the rat and rabbit, has failed to affect somatic growth (1). In contrast, the juvenile period is characterized by a near complete pituitary dependence of growth; body weight and skeletal growth were inhibited by 80 and 85% in Hx juvenile rats (5). Our prior studies, investigating the transition in pituitary regulation from fetus to adult, have documented a partial pituitary dependence of somatic growth, serum IGF, and IGFBP in Hx neonatal rats as early as postnatal d 6 (3) (4) (5) . Thus, our previous data have presented a clear pattern of pituitary dependence in the rat: the influence of pituitary hormones in maintaining normal somatic growth and the IGF-IGFBP axis is notable early in the neonatal period and becomes more pronounced with increasing postnatal age.
Using the model of the GH-deficient SDR, we have extended the scope of our investigation to an even earlier stage of development, while also avoiding the extensive fetal trauma incurred by previous invasive techniques. Because the pituitary content of GH is only detectable beginning at d 19 of gestation (30), we could speculate about the nature of the onset of GH contribution to growth within the limited time frame of late gestation.
From our data. we have formed a more distinct view of the
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also making it an unlikely contributor to the increase. Other alternatives such as decreased degradation of IGFBP-1, -3, or -4 as well as increased degradation of IGFBP-2 may also account for the binding protein increase.
mRNA. The livers of three GH-deficient and five GH-normal fetuses were randomly selected, and the tissues were evaluated for these individual animals. The levels of IGFBP-2 mRNA were comparable in the GH-deficient and the GH-normal fetuses. Thus, the increase of serum IGFBP in GH-deficient sera is not accompanied by an increase in the mRNA of the major IGFBP of the fetal period. This is consistent with the immunoprecipitation results, which indicate that the higher intensity of the 26-to 30-kD region in the GH-deficient group is not likely to be due to increased expression of IGFBP-2. Similar results of Northern role of the pituitary in early mammalian development: the GH regulation of somatic growth is clearly present in the late-gestation fetus. but its influence is not as extensive as in the postnatal period. We have shown previously in the Hx neonatal rat that. by postnatal d 25, body weight and tail length are inhibited by 50 and 32%, respectively. compared with sham control values (4, 5) . Growth in Hx juveniles nearly ceased, showing an inhibition in body weight and tail length of 80 and 85%, respectively (5) . In contrast, our fetal study demonstrated that body weight was inhibited by 14% and tail length remained unaffected in GH-deficient newborns. This illustrates the modest effect of GH deficiency during the fetal stage. The slight inhibition of body weight and absence of effect on tail length confirm the role of GH demonstrated in our neonatal studies, which shows a predominant effect of GH over soft tissue growth, rather than skeletal growth (5) .
The responses of individual organs in the SDR fetuses also revealed three important patterns of growth regulated by GH. As in the neonate, the brain and lungs were the only organs whose growth remained pituitary-independent. The brain's preservation, despite GH deficiency, may be a physiologic protective mechanism, allowing for continued neurologic function and development. despite the stress of suboptimal hormonal and metabolic conditions. Pituitary-independent growth may result from local (autocrine/paracrine) actions of IGF not reflected in serum IGF levels (31) or from the generation of other growth factors (i.c. nerve growth factor, fibroblast growth factor, and epidermal growth factor).
The majority of fetal organs examined exhibited moderate pituitary dependency. The kidneys, heart, and liver proved to be significantly affected by the absence of pituitary GH. However. although their growth was inhibited, the decrease in organ weight was proportional to changes in body weight. This finding is consistent with the moderate organ responses of Hx neonates (4) .
The limited inhibition of somatic growth and organ weights despite complete GH deficiency reflects, at least in part. situation, serum IGF-I1 concentrations arc nearly three times greater than the level of IGF-I in the fetus. Both IGF-I and -11 showed significant decreases in the GH-deficient fetuses compared with the GH-normal fetuses, demonstrating a role for GH in the regulation of fetal IGF. Serum IGF-I in the GH-deficient group, at 27% of GH-normal controls, showed a greater pituitary dependency than IGF-11, which, despite a 52% decrease, remained at levels higher than in the neonate after Hx (5). The pituitary dependence of IGF-I remains relatively constant in older animals, as demonstrated by its 75% decrease in Hx neonates (5) . However. IGF-I1 shows an increasing pituitary dependence with age, reflected in its 80% inhibition in the Hx neonate (5) .
In the fetus. serum IGF-I1 levels are high (32) even before the presence of GH is detected in the pituitary at d 19 of gestation (30) . Evidence in prior studies has indirectly supported the role of IGF-I1 as the major fetal growth regulator (33). Through selective targeting of the IGF-I1 gene in mice, DeChiara cJt a/. (34) have shown that IGF-I1 is an important regulator of approximately 40% of early (by embryonic d 16) prenatal growth but is ineffective in the postnatal period. This indicates the prominent effect of IGF-I1 early in fetal life, independent of the pituitary. Furthermore, our findings that continuous infusion of IGF-I1 fails to increase somatic growth in the Hx neonatal rat supports its exclusive role as a somatic growth factor prenatally in the rat ( 3 1).
In our previous studies. we have shown that the gradual decline from elevated levels of IGF-I1 in the early postnatal period is accelerated by Hx at d 6 (4, 5) . GH replacement in neonates returned IGF-I1 to sham values. thereby demonstrating its importance in regulating serum IGF-I1 levels in the immediate postnatal period (4, 5) . Although serum IGF-I1 is inhibited by more than 50% in GH-deficient fetuses, its continued expression reflects a partial independence of the pituitary and may account for the relatively modest effect of complete GH deficiency on somatic growth in the neonatal rat. The near normal growth of the GH-deficient fetuses, like the persistent 40% growth rate in Hx neonates. may result from higher tissue levels of both IGF, allowing for increased autocrine/paracrine growth-promoting activity not reflected in serum levels. Also. fetal tissue may have enhanced sensitivity to lower IGF levels. an increased concentration of IGF receptors, or IGF-sensitive cell populations [i.e. Another contributing factor to the partial preservation of somatic growth in GH-deficient fetuses may involve their increased expression of fetal binding proteins. In the sera from the GH-deficient group, the 26-to 30-kD binding protein complex showed a marked increase, compared with GH-normal rats, as measured by Western ligand blot. The IGFBP may alter IGF degradation and clearance and maximize the anabolic effects of IGF, resulting in more favorable use of limited calories. which is necessary in preserving somatic growth and organs such as the brain. Although the understanding of IGFBP function in whole animals is not yet complete, studies have shown that IGFBP may facilitate the peripheral actions of IGF at target tissues (37-39). Increased IGFBP function may thus help to explain the continued maintenance of organs and somatic growth despite GH deficiency.
However. the results of immunoprecipitation with a-Hec 1 antibody, deglycosylation with Endo F, and Northern analysis eliminate the major neonatal binding protein. IGFBP-2, or IGFBP-1, IGFBP-3, or IGFBP-4 as likely sources of the increased intensity of the 26-to 30-kD band in GH-deficient sera. This implies the presence of specific binding protein(s) operative primarily in the perinatal period. Further investigation is needed into the nature and function of these fetallneonatal binding proteins. The expression of IGFBP-5 mRNA has been shown to be very low or absent in the liver (40) and. therefore, could not be explored in our studies. For future studies. we will investigate the effects of GH deficiency on IGFBP-5 expression in other fetal tissues such as the kidney. heart. and lung (40).
The production by the human placenta of GH variants. which have been found to stimulate growth in transgenic mice. may present difficulties in extrapolating from our studies to the human (41). Although the hGH variant is found to be selectively secreted into the maternal circulation (42), there may be a low but suflicient level of the variant directed into the fetal bloodstream to prevent GH deficiency in the fetus. In the rat, however, it is not yet clear whether such placental variants exist. Although some portion of rat fetal growth may possibly be attributed to such a cause. the primary contribution of the GH variant would more likely be to maternal metabolism. as in humans.
The data presented here offer insight into the complex role of the pituitary during fetal development in the rat. Through the isolated GH mutation in the SDR. we have been able to focus specifically on GH function in the late gestation fetus. Many of the effects of GH in the late gestation fetus on body weight. organ growth. IGF, and IGFBP are consistent with our expectations from previous studies in neonatal. juvenile, and adult rats. We have shown the pituitary control of somatic growth in the fetus to be modest but significant. As in the neonate. GH in the fetus is primarily a regulator of soft-tissue growth and not skeletal growth. Three patterns of organ response were observed, with the brain and lungs being the only organs whose growth remained completely pituitary-independent. In addition, GH control over both IGF was clearly established by the end of the prenatal period. The marked increase in the 26-to 30-kD BP in GHdeficient rats indicates a role for GH in IGFBP regulation in the fetus, which may, in turn. regulate IGF action.
